TENOSYNOVIAL GIANT CELL TUMOR
Clinical trials for TENOSYNOVIAL GIANT CELL TUMOR explained in plain language.
Never miss a new study
Get alerted when new TENOSYNOVIAL GIANT CELL TUMOR trials appear
Sign up with your email to follow new studies for TENOSYNOVIAL GIANT CELL TUMOR, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug shows promise for rare joint tumor
Disease control OngoingThis phase 3 trial tests the drug pexidartinib in 40 adults with tenosynovial giant cell tumor (TGCT), a rare, non-cancerous growth in joints that causes pain and limits movement. The study focuses on people whose tumors are severe and cannot be helped by surgery. Researchers are…
Matched conditions: TENOSYNOVIAL GIANT CELL TUMOR
Phase: PHASE3 • Sponsor: Daiichi Sankyo Co., Ltd. • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New drug shows promise for rare joint tumor in early trial
Disease control OngoingThis study tests a drug called vimseltinib in people with a rare joint tumor (tenosynovial giant cell tumor, or TGCT) and advanced solid tumors. The drug blocks a protein that helps these tumors grow. The trial has two phases: first, finding the safest dose, then expanding to see…
Matched conditions: TENOSYNOVIAL GIANT CELL TUMOR
Phase: PHASE1, PHASE2 • Sponsor: Deciphera Pharmaceuticals, LLC • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New pill shows promise for rare joint tumor in Late-Stage trial
Disease control OngoingThis Phase 3 trial tests whether the drug Pimicotinib (ABSK021) can shrink tumors and improve symptoms in people with tenosynovial giant cell tumor (TGCT), a rare, non-cancerous growth in joints that cannot be surgically removed. About 94 adults will receive either the drug or a …
Matched conditions: TENOSYNOVIAL GIANT CELL TUMOR
Phase: PHASE3 • Sponsor: Abbisko Therapeutics Co, Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New pill could shrink rare joint tumors without surgery
Disease control OngoingThis phase 3 trial tests vimseltinib, an oral drug, for tenosynovial giant cell tumor (TGCT) when surgery isn't possible. About 123 adults with symptomatic TGCT will receive either vimseltinib or a placebo for 24 weeks, then all can get the drug. The main goal is to see if the dr…
Matched conditions: TENOSYNOVIAL GIANT CELL TUMOR
Phase: PHASE3 • Sponsor: Deciphera Pharmaceuticals, LLC • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New drug could shrink rare joint tumors without surgery
Disease control OngoingThis study tests an investigational drug called emactuzumab for people with a rare joint tumor (TGCT) that can't be removed surgically. About 128 participants will receive either the drug or a placebo to see if it shrinks tumors and improves joint function. The goal is to offer a…
Matched conditions: TENOSYNOVIAL GIANT CELL TUMOR
Phase: PHASE3 • Sponsor: SynOx Therapeutics Limited • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC